Trial Profile
A Phase 3, Multi-Center, Open Label Study To Evaluate The Long-Term Safety Of Monotherapy Sitaxsentan Sodium And Combination Therapy With Sitaxsentan Sodium And Sildenafil Citrate In Subjects With Pulmonary Arterial Hypertension
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 24 Aug 2016
Price :
$35
*
At a glance
- Drugs Sildenafil (Primary) ; Sitaxentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Pfizer
- 12 May 2014 New trial record
- 18 Apr 2011
- 10 Feb 2011